Press Releases

Press Releases

Samsung Biologics signs CDO(Contract Development Organization) contract with GI Innovation

Strategic Partnership for Development and Manufacturing

Samsung Biologics (CEO: Tae Han Kim) and GI Innovation (CEO: Soo Yeon Nam) signed a Contract Development Organization (CDO) contract for immunochemotherapy at Samsung Biologics headquarters on Thursday.

GI Innovation signed this second contract with Samsung Biologics based on their satisfaction with the high quality and production services received during their first project with Samsung Biologics in June of last year.

This agreement is the first among a five, multi-project deal, and Samsung Biologics will provide CDO services from the development of cell lines to the production of Phase I drug substances to GI Innovation, which is also the world's first bio-venture company to explore the development of new drugs through the combination of microbiome (human microorganism) and protein drugs.

This deal is expected to further leverage Samsung Biologics leading CDO technology and capacity with GI Innovation’s competitive candidates to accelerate new drug development.

The CDO market has grown at a CAGR of over 15%, and as the development of new biopharmaceuticals has increased, small and medium-sized biotech companies have outsourced development and production to CDMOs. In addition, the CDO business is becoming more significant in the industry, as it is naturally linked to the CMO (Contract Manufacturing Organization) business in the future.

In 2018, Samsung Biologics launched its CDO business and within a year secured new drug development projects comprising of eight domestic and overseas companies including GI Innovation, quickly establishing a track record of success as a globally advanced player in terms of speed, price competitiveness, quality, and efficiency.

"As Samsung Biologics provides consistent services for CRO (contract research), CDO (contract development) and CMO (contract manufacturing), biopharmaceutical companies will dramatically reduce costs and time,” said Dr. Tae Han Kim, “We will do our best to help domestic bio-venture companies, including GI Innovation, advance into the global market and commercialize their products through our CDO technology."

"Thanks to Samsung Biologics’ CDMO business, we can overcome the problem of producing high quality clinical test samples, the biggest barrier of bio venture companies,” said Dr. Nam, “We are very positive that global pharmaceutical companies interested in the R&D pipeline of GI Innovation will be able to access global new drug licensing (BLA) and biotech drug business through Samsung BioLogics' CDMO service. Through this collaboration, we wish to demonstrate the win-win model of venture firms and large corporations that the people and the government want.”
20195313291629.jpg

Samsung Biologics (CEO: Tae Han Kim) and GI Innovation (CEO: Soo Yeon Nam) signed a Contract Development Organization (CDO) contract for immunochemotherapy at Samsung Biologics headquarters on Thursday.

GI Innovation signed this second contract with Samsung Biologics based on their satisfaction with the high quality and production services received during their first project with Samsung Biologics in June of last year.

This agreement is the first among a five, multi-project deal, and Samsung Biologics will provide CDO services from the development of cell lines to the production of Phase I drug substances to GI Innovation, which is also the world's first bio-venture company to explore the development of new drugs through the combination of microbiome (human microorganism) and protein drugs.

This deal is expected to further leverage Samsung Biologics leading CDO technology and capacity with GI Innovation’s competitive candidates to accelerate new drug development.

The CDO market has grown at a CAGR of over 15%, and as the development of new biopharmaceuticals has increased, small and medium-sized biotech companies have outsourced development and production to CDMOs. In addition, the CDO business is becoming more significant in the industry, as it is naturally linked to the CMO (Contract Manufacturing Organization) business in the future.

In 2018, Samsung Biologics launched its CDO business and within a year secured new drug development projects comprising of eight domestic and overseas companies including GI Innovation, quickly establishing a track record of success as a globally advanced player in terms of speed, price competitiveness, quality, and efficiency.

"As Samsung Biologics provides consistent services for CRO (contract research), CDO (contract development) and CMO (contract manufacturing), biopharmaceutical companies will dramatically reduce costs and time,” said Dr. Tae Han Kim, “We will do our best to help domestic bio-venture companies, including GI Innovation, advance into the global market and commercialize their products through our CDO technology."

"Thanks to Samsung Biologics’ CDMO business, we can overcome the problem of producing high quality clinical test samples, the biggest barrier of bio venture companies,” said Dr. Nam, “We are very positive that global pharmaceutical companies interested in the R&D pipeline of GI Innovation will be able to access global new drug licensing (BLA) and biotech drug business through Samsung BioLogics' CDMO service. Through this collaboration, we wish to demonstrate the win-win model of venture firms and large corporations that the people and the government want.”

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION